Atrial Fibrillation Clinical Trial
— CAIOfficial title:
A Clinical Trial for the Assessment of the Safety and Performance of the Vimecon Laser Cardiac Ablation Instrument (CAI) for the Interventional Treatment of Paroxysmal Atrial Fibrillation (AF)
NCT number | NCT02770989 |
Other study ID # | VMC-001 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | March 2016 |
Est. completion date | September 2018 |
Verified date | October 2018 |
Source | Vimecon GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a prospective, non-randomized, single arm, multicenter, CE marking trial for patients with paroxysmal atrial fibrillation to undergo an ablation of the cardiac tissue near the PV.
Status | Terminated |
Enrollment | 1 |
Est. completion date | September 2018 |
Est. primary completion date | September 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Aged 18 to 75 years. 2. Patients with intention to be treated for paroxysmal atrial fibrillation. AND unresponsive to =1 antiarrhythmic drug (class I or III) AND at least 2 episodes in the last 12 months, 1 of them documented. 3. Patient should be on an anticoagulation therapy according to the international guidelines (per ACC/AHA//ESC Practice Guidelines) 4. Left atrial (LA) size < 50 mm 5. Symptomatic AF (EHRA-Score = 2) 6. Accessibility of femoral vein and pulmonary veins 7. All patients willing to comply with the study protocol for at least 12 months Exclusion Criteria: 1. 1. Inability to give written informed consent 2. NYHA Class III and IV 3. Hyperthyroidism 4. Reversible causes of the AF like Pericarditis, Electrolytic imbalance 5. Left Atrial Thrombus formation 6. Structural heart disease disturbing accessibility for AF ablation. 7. Valvular AF, permanent and long-standing persistent AF, currently present Atrial Flutter 8. Any valvular dysfunction more than II° 9. Systemic infections or endocarditis. 10. Impaired left ventricular function with an ejection fraction of less than 35% 11. Kidney dysfunction >Class III with a GFR of less than 35 mL per minute 12. TIA or stroke within the last 6 months 13. Pregnant and breastfeeding Women 14. Previous relevant cardiac surgery (e.g. ASD, PFO, Maze, AICD, pacemaker, congenital heart disorders or valve replacement). 15. Previous ablation of the pulmonary vein. 16. Known or suspected atrial myoma 17. Subject has co-morbid conditions that place the subject at an unacceptable risk (e.g., severe chronic obstructive pulmonary disease, hepatic failure, cerebral degenerative diseases, immunosuppressive abnormalities, hypercoagulable state, nervous system disease and hematological abnormalities.) 18. Contraindicated for the protocol defined anticoagulation plan (per ACC/AHA//ESC Practice Guidelines) 19. Patients with known allergic reactions to the local anesthetic, sedatives, x-ray dye, heparin, protamine, components of the catheter (platinum, iridium, stainless steel) or other agents administered during the procedure. 20. AV-Block IIº and IIIº 21. Contraindication for femoral vein and pulmonary veins access (e.g.: femoral Stent graft, excessive calcification, previous surgical interventions in or adjacent to the femoral veins that impede femoral access) 22. Contraindications for the transseptal approach (e.g.: previous inter-atrial septal patch or surgical interventions in or adjacent to the intro atrial septum) 23. MI in the last 3 months. 24. Enrolled in another clinical trial with a non-CE marked device which has not yet reached its primary endpoint |
Country | Name | City | State |
---|---|---|---|
Belgium | ZNA Middelheim | Antwerp | |
Czechia | Na Homolce Hospital | Prague | |
Germany | "Herz- und Diabeteszentrum NRW Klinik für Kardiologie" | Bad Oeynhausen |
Lead Sponsor | Collaborator |
---|---|
Vimecon GmbH |
Belgium, Czechia, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety assessment, free of any Major Adverse Events's or safety events within the first three (3) months after the treatment.. | Safety: • Evaluating the proportion of subjects free from experiencing Serious Adverse Events related to the catheter ablation procedure (Major Adverse Events's or safety events) within the first three (3) months after the treatment. Major adverse events (MAE, Safety events) associated with the catheter ablation procedure include: Cardiac tamponade Thromboembolic events including pulmonary embolism and stroke Complete heart block Acute myocardial infarction Phrenic nerve palsy Atrio-esophageal fistula Vascular complications Death |
< month-3 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |